According to Lancet medical journal, Covaxin shots are 50 per cent effective against symptomatic COVID-19 patients.

The study was conducted between April 15 and May 15 at AIIMS in New Delhi. Those who had symptoms and had undergone an RT-PCR test for coronavirus were part of the study.

<a href="https://www.wionews.com/world/a-positive-decision-new-zealand-includes-covishield-covaxin-in-list-of-recognised-vaccines-430229">Also Read:&nbsp;New Zealand includes Covishield, Covaxin in list of recognised vaccines</a>

The Lancet research took place when India was hit by the second wave with the Delta variant surging across the country.&nbsp;Lancet in an earlier study had declared Covaxin to be &nbsp;77.8 percent&nbsp;effective against symptomatic cases and 93.4 per cent against severe symptomatic cases.

India had rolled out its vaccination campaign on January 16 with Oxford's Covishield and Bharat Biotech's Covaxin&nbsp;with only&nbsp;healthcare workers and frontline staff given the vaccine jabs.

<a href="https://www.wionews.com/india-news/booster-dose-to-be-taken-6-months-after-covaxins-2nd-dose-bharat-biotech-cmd-428449">Also Read:&nbsp;Booster dose to be taken 6 months after Covaxin's 2nd dose: Bharat Biotech CMD</a>

Lancet informed the participants were divided into "two groups" on the basis of their RT-PCR result - symptomatic test-positive cases and symptomatic test-negative cases (controls).&nbsp;

"Cases and controls were then matched (1:1) on the basis of age and gender. Vaccination status was compared between cases and controls," it said.

<a href="https://www.wionews.com/world/indias-covaxin-to-be-added-to-uk-approved-list-from-november-22-427884">Also Read:&nbsp;India's Covaxin to be added to UK approved list from November 22</a>

The study pointed out that "vaccine effectiveness takes a few weeks, at least 14 days to develop and requires full two doses to achieve maximum effectiveness" although face masks and physical distancing should be followed at all times.

The report said vaccine effectiveness remained stable over the seven-week follow-up period after two doses were administered.&nbsp;The World Health Organization (WHO) had approved Covaxin for emergency use this month.

(With inputs from Agencies)

According to Lancet medical journal, Covaxin shots are 50 per cent effective against symptomatic COVID-19 patients. The study was conducted between April 15 and May 15 at AIIMS in New Delhi.

According to Lancet medical journal, Covaxin shots are 50 per cent effective against symptomatic COVID-19 patients. The study was conducted between April 15 and May 15 at AIIMS in New Delhi. Those who had symptoms and had undergone an RT-PCR test for coronavirus were part of the study. Also Read: New Zealand includes Covishield, Covaxin in list of recognised vaccines The Lancet research took place when India was hit by the second wave with the Delta variant surging across the country. Lancet in an earlier study had declared Covaxin to be 77.8 percent effective against symptomatic cases and 93.4 per cent against severe symptomatic cases. India had rolled out its vaccination campaign on January 16 with Oxford's Covishield and Bharat Biotech's Covaxin with only healthcare workers and frontline staff given the vaccine jabs. Also Read: Booster dose to be taken 6 months after Covaxin's 2nd dose: Bharat Biotech CMD Lancet informed the participants were divided into "two groups" on the basis of their RT-PCR result - symptomatic test-positive cases and symptomatic test-negative cases (controls). "Cases and controls were then matched (1:1) on the basis of age and gender. Vaccination status was compared between cases and controls," it said. Also Read: India's Covaxin to be added to UK approved list from November 22 The study pointed out that "vaccine effectiveness takes a few weeks, at least 14 days to develop and requires full two doses to achieve maximum effectiveness" although face masks and physical distancing should be followed at all times. The report said vaccine effectiveness remained stable over the seven-week follow-up period after two doses were administered. The World Health Organization (WHO) had approved Covaxin for emergency use this month. (With inputs from Agencies)

Covaxin 50 per cent effective against virus, says Lancet study

In India schools are open, kids are back in the schools but they are not vaccinated. The Drug Controller General of India (DCGI) is yet to approve the Covaxin rule out for children.

India: Covaxin yet to get DCGI nod for kids

covaxin-clinical-trials-for-kids

Covaxin Clinical Trials For Kids, News on Covaxin Clinical Trials For Kids, stories on Covaxin Clinical Trials For Kids, articles on Covaxin Clinical Trials For Kids, Covaxin Clinical Trials For Kids stories at Wion, Covaxin Clinical Trials For Kids news, Covaxin Clinical Trials For Kids latest news

covaxin clinical-trials-for-kids

Covaxin 50 per cent effective against virus, says Lancet study

India: Covaxin yet to get DCGI nod for kids